Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-Year data from the REFLEX study

Journal of Rheumatology

Volumn 39, Issue 12, 2012, Pages 2238-2246

  Keystone, Edward C ^a,b   Cohen, Stanley B ^c   Emery, Paul ^d   Kremer, Joel M ^e   Dougados, Maxime ^f   Loveless, James E ^g   Chung, Carol ^j   Wong, Pamela ^h   Lehane, Patricia B ⁱ   Tyrrell, Helen ⁱ  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c METROPLEX CLINICAL RESEARCH CENTER   (United States)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e ALBANY MEDICAL COLLEGE   (United States)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g St Luke's Rheumatology   (United States)

^h GENENTECH INC   (United States)

ⁱ ROCHE PRODUCTS LTD   (United Kingdom)

^j Biostatistics ^*  (United States)

more..

Author keywords

Biological therapy; CD20 antibody; Rheumatoid arthritis; Rituximab

Indexed keywords

ANTIINFECTIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ABSCESS; ADULT; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HEPATITIS B; HUMAN; JOINT RADIOGRAPHY; LUNG INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MUSCULOSKELETAL DISEASE; OBSERVATIONAL STUDY; OPEN STUDY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHARYNGITIS; PNEUMONIA; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSEUDALLESCHERIASIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; QUESTIONNAIRES; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870330803     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120573     Document Type: Article

References (23)

1. Dass S, Vital EM, Emery P. Rituximab: Novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2006;7:2559-70. (Pubitemid 44932458)
2. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
3. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-21.
4. Cohen SB, Keystone E, Genovese MC, Emery P, Peterfy C, Tak PP, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis 2010;69:1158-61.
5. Keystone EC, Fleischmann RM, Emery P, Dougados M, Williams S, Linnik MD, et al. Multiple courses of rituximab produce sustained efficacy in patients with rheumatoid arthritis with an inadequate response to one or more TNF inhibitors [abstract]. Arthritis Rheum 2010;62 Suppl:S133.
6. van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleischmann R, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with focus on adverse events of interest in RA patients. Ann Rheum Dis [in press].
7. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
8. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
9. van der Heijde D, Landewe R, van Vollenhoven R, Fatenejad S, Klareskog L. Level of radiographic damage and radiographic progression are determinants of physical function: A longitudinal analysis of the TEMPO trial. Ann Rheum Dis 2008;67:1267-70.
10. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56. (Pubitemid 34136571)
11. van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928-39. (Pubitemid 350262318)
12. van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010;37:2237-46.
13. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of RTX in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
14. Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41:1583-90. (Pubitemid 28459916)
15. Fleischmann RM. Progressive multifocal leukoencephalopathy following RTX treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009;60:3225-8.
16. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44. (Pubitemid 47492478)
17. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
18. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: What drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20.
19. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007;46:1191-9. (Pubitemid 47053782)
20. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
21. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: Open-label extension of the ATTEST Study. Ann Rheum Dis 2011;70:2003-7.
22. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al. Updated consensus statement on the use of RTX in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20.
23. Emery P, Mease PJ, Rubbert-Roth A, Curtis JR, Muller-Ladner U, Gaylis NB, et al. Retreatment with RTX based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: A retrospective pooled analysis. Rheumatology 2011;50:2223-32.